Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Directorate Change

18 Feb 2014 07:00

RNS Number : 2823A
Kromek Group PLC
18 February 2014
 



 

Kromek Group plc

("Kromek" or "the Company")

Directorate Change

 

Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, announces that Ms. Maria Charlotta Ginman-Jones (known as Ms. Charlotta Ginman) has been appointed to the Company's Board as a Non-Executive Director with immediate effect.

 

Ms. Ginman, aged 48, will chair the Company's Audit Committee and brings with her substantial experience in financial and operational management gained during her successful executive career in the global telecommunications and investment banking sectors.

 

Currently a Non-Executive Director of Wolfson Microelectronics, and a member of Wolfson's Audit Committee, Ms. Ginman began her career at Ernst & Young LLP joining in 1989 until 1994, and was then appointed to a series of senior roles in investment banking with JP Morgan, Deutsche Bank and UBS.

 

During a career with Nokia Corporation, Ms. Ginman held many different roles, beginning as a business controller in the company's imaging division and progressing to the role of director of finance and control of the company's service business. Ms. Ginman has overseen a number acquisitions during her tenure at Nokia and became Chief Financial Officer of Nokia's luxury mobile phone division, Vertu Corporation Ltd, in 2009. Ms Ginman led the carve out of Vertu Corporation Ltd from Nokia and successfully sold the business to a private equity group.

 

A chartered accountant, Ms. Ginman also holds an MSc in Economics from the Swedish School of Economics and Business Administration in Helsinki.

 

Commenting on the announcement, Arnab Basu, CEO of Kromek, commented: "We are very pleased to welcome Charlotta to our Board. We will benefit greatly from her knowledge and experience that she has gained during an impressive career and her appointment further strengthens our Board."

 

"Charlotta joins Kromek at a very exciting time. Since joining AIM, we have accelerated our development and we are building on the success achieved in recent years, as we work to realise the value of our world-class technology platform."

 

Previous Directorships

Wolfson Microelectronics plc, Non-executive Director

Current Directorships

Ms. Ginman is not currently a director of any other company.

 

There is no other information that is required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules in relation to the appointments of Ms. Ginman.

 

-ends-

 

For further information, please contact:

Kromek Group Plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley/ Grishma Patel

Broking

Adam Pollock/ Charlie Leigh-Pemberton

 

Tel: 020 7886 2500

Tavistock Communications

Matt Ridsdale

Andrew Dunn

Tel: 020 7920 3150

 

About Kromek

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 70 granted patents and 110 pending applications.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFLTFEIDLIS
Date   Source Headline
2nd Sep 20158:56 amRNSHolding(s) in Company
28th Aug 20151:18 pmRNSHolding(s) in Company
28th Aug 201512:13 pmRNSTotal Voting Rights
28th Aug 20159:08 amRNSHolding(s) in Company
26th Aug 20153:59 pmRNSHolding(s) in Company
20th Aug 20158:23 amRNSHolding(s) in Company
17th Aug 201512:11 pmRNSResults of Firm Placing and Open Offer
30th Jul 201512:16 pmRNSDirector Share Purchase
30th Jul 201511:39 amRNSFirm Placing and Open Offer Timetable
30th Jul 20157:01 amRNSFirm Placing and Open Offer to raise up to £11.0m
30th Jul 20157:01 amRNSFinal Results
1st Jul 20155:13 pmRNSHolding(s) in Company
1st Jul 20155:07 pmRNSHolding(s) in Company
18th May 20157:00 amRNSMultiple contract wins with global OEMs
28th Apr 20157:00 amRNSChange of Adviser
17th Apr 20157:00 amRNSBusiness and Trading Update
17th Apr 20157:00 amRNSKromek awarded further contract by DARPA
27th Mar 20157:00 amRNSDirectorate Change
16th Mar 20157:00 amRNSCredit facility with HSBC
10th Feb 20158:56 amRNSBlock Listing Update
9th Feb 20157:00 amRNSGlobal contract wins across all segments
14th Jan 20157:00 amRNSInterim Results
14th Jan 20157:00 amRNSExtension to nuclear detection contract with DARPA
11th Dec 20147:00 amRNSKromek Contract Wins
9th Oct 20149:15 amRNSDirector's Dealing
1st Oct 201411:56 amRNSResult of AGM
22nd Sep 20147:00 amRNSProgress with global OEM contract
10th Sep 20145:46 pmRNSAnnual Report and Accounts and Notice of AGM
28th Aug 20147:00 amRNSFinal Results
4th Aug 20147:00 amRNSContract Win
31st Jul 20147:00 amRNSBlock Listing Update and Additional Listing
22nd Jul 20147:00 amRNSContract Win and Update on Trading
23rd Jun 20147:00 amRNSContract Wins
5th Jun 20147:00 amRNSNew Loan Facility
15th Apr 20147:00 amRNSDirector/PDMR Shareholding
7th Apr 20145:03 pmRNSDirector/PDMR Shareholding
4th Apr 20147:00 amRNSNew Contract Signed in Medical Imaging Market
28th Mar 20147:01 amRNSTrading Statement
27th Feb 20147:00 amRNSNew Orders Received in Medical Imaging
18th Feb 20147:00 amRNSDirectorate Change
30th Jan 20143:56 pmRNSAdditional Listing
8th Jan 20147:00 amRNSHalf Yearly Report
10th Dec 20137:00 amRNSDirectorate Change
27th Nov 20137:00 amRNSBottle Scanner Orders and New Accreditation
5th Nov 20137:00 amRNSOrders and payments received from global OEMs
31st Oct 20131:28 pmRNSTotal Voting Rights
24th Oct 201311:44 amRNSHolding(s) in Company
21st Oct 20136:08 pmRNSHolding(s) in Company
16th Oct 20137:00 amRNSAdmission and First Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.